Ask AI
ProCE Banner Activity

Bridging the Gap in sHTG and FCS Treatment With Novel RNA-Based Therapies

Clinical Thought

Improve your practice by understanding how to better identify and diagnose patients with severe hypertriglyceridemia or familial chylomicronemia syndrome and the current evidence for novel RNA-based therapies that are bridging the treatment gap for those who do not respond to traditional therapy.

Released: May 15, 2025

Expiration: May 14, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by a grant from Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

Disclosure

Primary Author

Christie M. Ballantyne, MD: consultant/advisor/speaker: 89bio, Abbott Diagnostics, Amarin, Amgen, Arrowhead, AstraZeneca, Denka Seiken, Esperion, Genentech, Illumina, Ionis, Lilly, Merck, New Amsterdam, Novartis, Novo Nordisk, Roche Diagnostics.